Biosimilar tocilizumab proves to be a cost-effective treatment for rheumatoid arthritis in Spain, enhancing access to ...
Australia's adoption of etanercept biosimilars enhances access to rheumatoid arthritis treatments, maintaining treatment ...
Major advancements in biosimilars emerge in Europe and Middle East and North Africa (MENA) region, enhancing patient access ...
Biosimilars and generics drive significant health care savings, yet a concerning lack of biosimilar development for biologics ...
Recent approvals and settlements enhance global access to aflibercept biosimilars, improving treatment options for ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
Number 5: The FDA has approved Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq), the sixth pair of denosumab biosimilars to receive the green light from the agency. The approvals, granted to ...
The European Commission (EC) approves new biosimilars for osteoporosis and eye conditions, enhancing treatment options and ...
The FDA has approved Bosaya and Aukelso, expanding affordable denosumab biosimilars for osteoporosis and bone-related cancers and enhancing treatment options.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback